Athena Athena

X
[{"orgOrder":0,"company":"Syntekabio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Syntekabio Presents Nonclinical Data of immuno-oncologic agent STB-C017 at the 2020 AACR meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Syntekabio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Syntekabio Found Repurposable Covid-19 Drug Candidates Stronger than Remdesivir","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"SOUTH KOREA","productType":"Undisclosed","productStatus":"Undisclosed","date":"September 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"}]

Find Clinical Drug Pipeline Developments & Deals by Syntekabio

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Syntekabio selected two drug materials as viable COVID-19 treatment candidates through an artificial intelligence program. The drugs, administered together in animal models, have demonstrated 94.3 percent recovery rate in affected lungs.

            Lead Product(s): Undisclosed

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 03, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Triple combination therapy of STB-C017, PD-1, CTLA-4 immune checkpoint inhibitors (ICIs) presented complete remission (CR) of tumor and long-term survival benefit.

            Lead Product(s): STB-C017

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 15, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY